ClinicalTrials.gg
CompletedNCT00559754Updated Nov 10, 2014Results posted

A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.

A Phase 2 interventional study of bevacizumab [Avastin] and Docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-10.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
120th of 248
72 · median 68
Started
2007
with 18 others
Phase 2
157 of 264
11 open now
Registered
144th of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 120th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2007, is one of 157 in phase 2, and was the 144th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of a combination of Avastin and docetaxel following cyclophosphamide and doxorubicin, in patients with HER2 negative operable breast cancer. Patients will receive 4 x 3 week cycles of chemotherapy with doxorubicin (60mg/m2 iv on day 1 of each cycle) and cyclophosphamide (600mg/m2 iv on day 1 of each cycle). They will then receive 4 x 3 week cycles of docetaxel (75mg/m2 on day 1 of each cycle) in combination with Avastin (15mg/kg on day 1 of each cycle). The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >=18 years of age;
  • primary -negative operable breast cancer;
  • tumor >2cm in size;
  • performance status 0-1.

Exclusion criteria

Exclusion Criteria:

  • previous treatment for breast cancer;
  • disease;
  • current or recent (within 10 days of first dose of Avastin) use of aspirin (>325mg/day) or full-dose anticoagulants for therapeutic purposes;
  • cardiovascular disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: Docetaxel · Drug: Standard chemotherapy

Interventions

  • 15mg/kg iv on day 1 of each 3 week cycle

  • 75mg/m2 iv on day 1 of each 3 week cycle

  • DrugStandard chemotherapy

    As prescribed

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pathological Complete Response (pCR)

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria: 1) the primary tumor was Grade 5 (no malignant cells identified at the location of the primary tumor (ductal carcinoma in situ may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at evaluation of the surgical piece was 0 centimeters (cm); and 4) the pathological staging of the tumour from the surgical piece was pT0pN0pM0, the stage is not applicable (NA). It will only be considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.

    Time frame: After Week 24 (surgery)

Secondary outcomes

  1. Percentage of Participants With Objective Clinical Response

    Overall clinical response is the best response obtained through physical examination and/or radiological tests after completion of chemotherapy cycles. The percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) and was categorized as clinical response (CR+PR) or clinical benefit (CR+PR+ no change \[NC\]). Per RECIST, CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met.

    Time frame: Within 28 days of enrollment, Weeks 12 and 24

  2. Percentage of Participants With Breast-Conserving Surgery

    Breast-conserving surgery was defined as lumpectomy + lymphadenectomy (LA), segmentectomy + LA, quadrantectomy + LA, or other (including sentinal node extirpation tumorectomy).

    Time frame: Week 24

  3. Percentage of Participants With pCR by Proliferation of Ki67

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Biomarker Ki67 proliferation was defined as low (less than \[\<\]15% ) and high (≥15%).

    Time frame: After Week 24 (surgery)

  4. Percentage of Participants With pCR by Kisspeptin (KISS1) Amplification

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).

    Time frame: After Week 24 (surgery)

  5. Percentage of Participants With pCR by KISS1 Protein Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

    Time frame: After Week 24 (surgery)

  6. Percentage of Participants With pCR by Vascular Endothelial Growth Factor Receptor (VEGFR) Amplification

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEFGR amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).

    Time frame: After Week 24 (surgery)

  7. Percentage of Participants With pCR by VEGFR Protein Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

    Time frame: After Week 24 (surgery)

  8. Percentage of Participants With pCR by Hypoxia Inducible Factor (HIF) Protein Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

    Time frame: After Week 24 (surgery)

  9. Percentage of Participants With pCR by Endothelial Nitric Oxide Synthase (ENOS) Protein Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

    Time frame: After Week 24 (surgery)

  10. Percentage of Participants With pCR by Angiotension Protein Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Angiotensin protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

    Time frame: After Week 24 (surgery)

  11. Percentage of Participants With pCR by Vascular Endothelial Growth Factor (VEGF) Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  12. Percentage of Participants With pCR by VEGFR Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  13. Percentage of Participants With pCR by Phosphorylated AKT (pAKT) Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pAKT gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  14. Percentage of Participants With pCR by HIF Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  15. Percentage of Participants With pCR by Insulin-Like Growth Factor (IGF) Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. IGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  16. Percentage of Participants With pCR by ENOS Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  17. Percentage of Participants With pCR by Phosphorylated MAP Kinase (pMAPK) Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pMAPK gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  18. Percentage of Participants With pCR by Angiotensin II Receptor Type I (AGTR) Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. AGTR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  19. Percentage of Participants With pCR by KISS1 Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

  20. Percentage of Participants With pCR by RKISS1 Gene Expression

    The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. RKISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

    Time frame: After Week 24 (surgery)

07

Results

Posted Nov 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Started72
Completed61
Not completed11
Withdrew: Disease progression1
Withdrew: Adverse event5
Withdrew: Protocol violation1
Withdrew: Investigator criteria2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryPercentage of Participants With Pathological Complete Response (pCR)

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria: 1) the primary tumor was Grade 5 (no malignant cells identified at the location of the primary tumor (ductal carcinoma in situ may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at evaluation of the surgical piece was 0 centimeters (cm); and 4) the pathological staging of the tumour from the surgical piece was pT0pN0pM0, the stage is not applicable (NA). It will only be considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With Pathological Complete Response (pCR)
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Percentage of Participants With Pathological Complete Response (pCR)24.2 (14.5 to 36.4)
SecondaryPercentage of Participants With Objective Clinical Response

Overall clinical response is the best response obtained through physical examination and/or radiological tests after completion of chemotherapy cycles. The percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) and was categorized as clinical response (CR+PR) or clinical benefit (CR+PR+ no change \[NC\]). Per RECIST, CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met.

Time frame:
Within 28 days of enrollment, Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Clinical Response
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
CR+PR88.9 (79.3 to 95.1)
CR+PR+NC98.6 (92.5 to 99.9)
SecondaryPercentage of Participants With Breast-Conserving Surgery

Breast-conserving surgery was defined as lumpectomy + lymphadenectomy (LA), segmentectomy + LA, quadrantectomy + LA, or other (including sentinal node extirpation tumorectomy).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Breast-Conserving Surgery
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Percentage of Participants With Breast-Conserving Surgery62.7
SecondaryPercentage of Participants With pCR by Proliferation of Ki67

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Biomarker Ki67 proliferation was defined as low (less than \[\<\]15% ) and high (≥15%).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Proliferation of Ki67
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
High proliferative index (n=50)24.0
Low proliferative index (n=15)13.3
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.4915
SecondaryPercentage of Participants With pCR by Kisspeptin (KISS1) Amplification

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Kisspeptin (KISS1) Amplification
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Anueploid (n=8)12.5
Normal (n=13)30.77
Amplification (n=2)50.0
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Chi-squared · p = 0.4864
SecondaryPercentage of Participants With pCR by KISS1 Protein Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by KISS1 Protein Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
No expression (n=18)27.8
Normal (n=3)66.7
Augmented expression (n=4)50.0
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.3613
SecondaryPercentage of Participants With pCR by Vascular Endothelial Growth Factor Receptor (VEGFR) Amplification

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEFGR amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Vascular Endothelial Growth Factor Receptor (VEGFR) Amplification
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Anueploid (n=1)0
Normal (n=18)33.3
Amplification (n=4)0
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.6605
SecondaryPercentage of Participants With pCR by VEGFR Protein Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by VEGFR Protein Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
No expression (n=7)28.6
Normal (n=5)40.0
Augmented expression (n=10)20.0
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.8311
SecondaryPercentage of Participants With pCR by Hypoxia Inducible Factor (HIF) Protein Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Hypoxia Inducible Factor (HIF) Protein Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
No expression (n=25)40.0
Normal (n=8)12.5
Augmented expression (n=5)60.0
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.2230
SecondaryPercentage of Participants With pCR by Endothelial Nitric Oxide Synthase (ENOS) Protein Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Endothelial Nitric Oxide Synthase (ENOS) Protein Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
No expression (n=24)29.2
Normal (n=10)40.0
Augmented expression (n=4)25.0
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.8696
SecondaryPercentage of Participants With pCR by Angiotension Protein Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Angiotensin protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Angiotension Protein Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
No expression (n=14)7.1
Normal (n=1)0.0
Augmented expression (n=11)63.6
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.0074
SecondaryPercentage of Participants With pCR by Vascular Endothelial Growth Factor (VEGF) Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Vascular Endothelial Growth Factor (VEGF) Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=1)100.0
Gene expression below housekeeping level (n=33)30.3
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.3235
SecondaryPercentage of Participants With pCR by VEGFR Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by VEGFR Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=7)0.0
Gene expression below housekeeping level (n=27)40.7
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.0693
SecondaryPercentage of Participants With pCR by Phosphorylated AKT (pAKT) Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pAKT gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Phosphorylated AKT (pAKT) Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=0)NA
Gene expression below housekeeping level (n=34)32.4
SecondaryPercentage of Participants With pCR by HIF Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by HIF Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=9)44.4
Gene expression below housekeeping level (n=25)28.0
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 0.4254
SecondaryPercentage of Participants With pCR by Insulin-Like Growth Factor (IGF) Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. IGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Insulin-Like Growth Factor (IGF) Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=0)NA
Gene expression below housekeeping level (n=34)32.4
SecondaryPercentage of Participants With pCR by ENOS Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by ENOS Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=1)0
Gene expression below housekeeping level (n=33)33.3
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 1.0000
SecondaryPercentage of Participants With pCR by Phosphorylated MAP Kinase (pMAPK) Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pMAPK gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Phosphorylated MAP Kinase (pMAPK) Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=30)33.3
Gene expression equal to housekeeping level (n=1)0
Gene expression below housekeeping level (n=3)33.3
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 1.0000
SecondaryPercentage of Participants With pCR by Angiotensin II Receptor Type I (AGTR) Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. AGTR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by Angiotensin II Receptor Type I (AGTR) Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=0)NA
Gene expression below housekeeping level (n=33)30.3
SecondaryPercentage of Participants With pCR by KISS1 Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by KISS1 Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=1)0.0
Gene expression below housekeeping level (n=33)33.3
Statistical analysis
  • Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel · Fisher Exact · p = 1.0000
SecondaryPercentage of Participants With pCR by RKISS1 Gene Expression

The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. RKISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).

Time frame:
After Week 24 (surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With pCR by RKISS1 Gene Expression
percentage of participantsDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Gene expression above housekeeping level (n=0)NA
Gene expression below housekeeping level (n=34)32.4

Adverse events

Collected over Adverse events (AEs) were reported from the day of informed consent to the last date of contact for all participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel—13/72 (18.1%)71/72 (98.6%)
Most frequent serious events
Most frequent serious events
EventDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Febrile neutropaeniaInfections and infestations6/72
Neutrophils/granulocytesBlood and lymphatic system disorders4/72
Mucositis/stomatitisGastrointestinal disorders2/72
Infection with normal absolute neutrophil count (ANC) or grade 1 or 2 neutrophilsInfections and infestations1/72
VomitingGastrointestinal disorders1/72
Most frequent other events
Showing 10 of 32
Most frequent other events
EventDoxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Fatigue (asthenia, lethargy, malaise)General disorders44/72
Mucositis/stomatitisGastrointestinal disorders43/72
NauseaGastrointestinal disorders43/72
Hair loss/alopeciaSkin and subcutaneous tissue disorders36/72
PainGeneral disorders36/72
VomitingGastrointestinal disorders24/72
DiarrhoeaGastrointestinal disorders17/72
Infection with normal ANC or grade 1 or 2 neutrophilsInfections and infestations17/72
ConstipationGastrointestinal disorders14/72
FeverGeneral disorders14/72

Baseline characteristics

Intent to Treat (ITT) Population: all participants included in the study.

Age, Continuous
Age, Continuous(years)Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Mean47.22 ± 9.85
Sex/Gender, Customized
Sex/Gender, Customized(participants)Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel
Female72
08

Study locations

6 sites
  • Sabadell, Barcelona, Barcelona 08208, Spain
  • Cordoba, 14004, Spain
  • Jaen, 23007, Spain
  • Lerida, 25198, Spain
  • Malaga, 29010, Spain
  • Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2007
First posted
Nov 16, 2007
Start
Dec 2007
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Nov 10, 2014
Last update
Nov 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00559754
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 16, 2007
Start date
Dec 2007
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Nov 10, 2014
Last update
Nov 10, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion